Extended FTC review adds wrinkle to Sanofi's $2.9B Provention Bio buyout
Sanofi is extending the deadline for its $2.9 billion acquisition of Provention Bio to give antitrust regulators more time to review the deal.
The French pharma giant withdrew and refiled the Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act “following informal discussions with the staff of the” Federal Trade Commission (FTC), it said in an SEC filing. The agency, it added, needed more time to look at the deal and “information recently provided to them.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.